Biofrontera Inc.
Close on Oct 19, 2026
- Market cap
- $10.41M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | $12.00M | $-0.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $10.10M | $-0.41 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | Before market open | $17.10M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | $7.00M | $-0.62 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | During market hours | $9.00M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | During market hours | $8.60M | $-0.47 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 21, 2025 | Before market open | $12.60M | $-0.19 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $9.00M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 15, 2024 | During market hours | – | – | – |
Press releases
Announcements Biofrontera filed with the SEC
Announces FDA Approval of Ameluz ® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Other events · EX-99.1 to Form 8-K
Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
Results of operations · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne
Regulation FD disclosure · EX-99.1 to Form 8-K
Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
Other events · EX-99.1 to Form 8-K
Announces Positive Results in Phase 3 Study of Ameluz ® PDT for Actinic Keratoses on the Extremities, Neck,
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35%
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. announces sale of license to Xepi ® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Closes Purchase of All Ameluz ® and RhodoLED ® US Assets from Biofrontera AG
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Appoints George Jones as Chief Commercial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
Regulation FD disclosure · EX-99.1 to Form 8-K
INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
Other events · EX-99.1 to Form 8-K
2025 ANNUAL MEETING OF STOCKHOLDERS OF BIOFRONTERA INC.
Other events · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Closes a $4.2 Million Senior Secured Convertible Note
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz ® -Photodynamic Therapy (PDT) Regarding The
Regulation FD disclosure · EX-99.1 to Form 8-K
Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED ® XL Lamp
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
Other events · EX-99.1 to Form 8-K
Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Announces Private Placement of Up To $16.0 Million
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz ® to Permit Up to Three Tubes per Use
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Receives FDA Approval for New Formulation of Ameluz ®
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Preliminary Third Quarter Revenues
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Discussion and Analysis of Financial Condition and Results of Operations
Other events · EX-99.2 to Form 8-K
Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K